These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 34537760)

  • 1. METTL3-mediated m6A modification of KIF3C-mRNA promotes prostate cancer progression and is negatively regulated by miR-320d.
    Ma H; Zhang F; Zhong Q; Hou J
    Aging (Albany NY); 2021 Sep; 13(18):22332-22344. PubMed ID: 34537760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. METTL3-mediated m6A modification of pri-miR-148a-3p affects prostate cancer progression by regulating TXNIP.
    Li G; Liu J; Wang Y; Liu H; Fu J; Zhao Y; Huang Y
    Environ Toxicol; 2023 Oct; 38(10):2377-2390. PubMed ID: 37449729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. METTL3 promotes prostate cancer progression by regulating miR-182 maturation in m6A-dependent manner.
    Wang D; Wang X; Huang B; Zhao Y; Tu W; Jin X; Shao Y; Zhu Y; Lu G
    Andrologia; 2022 Aug; 54(7):1581-1591. PubMed ID: 35413135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. METTL3 facilitates prostate cancer progression via inducing HOXC6 m6A modification and stabilizing its expression through IGF2BP2-dependent mechanisms.
    He P; Liu X; Yu G; Wang Y; Wang S; Liu J; An Y
    Mol Cell Biochem; 2024 Jul; 479(7):1707-1720. PubMed ID: 38822192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silencing of METTL3 effectively hinders invasion and metastasis of prostate cancer cells.
    Chen Y; Pan C; Wang X; Xu D; Ma Y; Hu J; Chen P; Xiang Z; Rao Q; Han X
    Theranostics; 2021; 11(16):7640-7657. PubMed ID: 34335955
    [No Abstract]   [Full Text] [Related]  

  • 6. Upregulated METTL3 promotes metastasis of colorectal Cancer via miR-1246/SPRED2/MAPK signaling pathway.
    Peng W; Li J; Chen R; Gu Q; Yang P; Qian W; Ji D; Wang Q; Zhang Z; Tang J; Sun Y
    J Exp Clin Cancer Res; 2019 Sep; 38(1):393. PubMed ID: 31492150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. m6A-modified circASXL1 promotes proliferation and migration of ovarian cancer through the miR-320d/RACGAP1 axis.
    Tian Q; Mu Q; Liu S; Huang K; Tang Y; Zhang P; Zhao J; Shu C
    Carcinogenesis; 2023 Dec; 44(12):859-870. PubMed ID: 37738681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross talk between RNA N6-methyladenosine methyltransferase-like 3 and miR-186 regulates hepatoblastoma progression through Wnt/β-catenin signalling pathway.
    Cui X; Wang Z; Li J; Zhu J; Ren Z; Zhang D; Zhao W; Fan Y; Zhang D; Sun R
    Cell Prolif; 2020 Mar; 53(3):e12768. PubMed ID: 31967701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. METTL3 promote tumor proliferation of bladder cancer by accelerating pri-miR221/222 maturation in m6A-dependent manner.
    Han J; Wang JZ; Yang X; Yu H; Zhou R; Lu HC; Yuan WB; Lu JC; Zhou ZJ; Lu Q; Wei JF; Yang H
    Mol Cancer; 2019 Jun; 18(1):110. PubMed ID: 31228940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiR-4429 prevented gastric cancer progression through targeting METTL3 to inhibit m
    He H; Wu W; Sun Z; Chai L
    Biochem Biophys Res Commun; 2019 Oct; 517(4):581-587. PubMed ID: 31395342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. METTL3 m6A-dependently promotes miR-21-5p maturation to accelerate choriocarcinoma progression via the HIF1AN-induced inactivation of the HIF1A/VEGF pathway.
    Ye K; Li L; Wu B; Wang D
    Genes Genomics; 2022 Nov; 44(11):1311-1322. PubMed ID: 36074324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. m6A methyltransferase METTL3 promotes the progression of prostate cancer via m6A-modified LEF1.
    Ma XX; Cao ZG; Zhao SL
    Eur Rev Med Pharmacol Sci; 2020 Apr; 24(7):3565-3571. PubMed ID: 32329830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methyltransferase-like 3 (METTL3) mediated N6-methyladenosine (m6A) modifications facilitate mir-25-3p maturation to promote gastrointestinal stromal tumors (GISTs) progression.
    Qian K; Xu W; Xia X; Ding J
    Genes Genomics; 2022 Dec; 44(12):1519-1530. PubMed ID: 36040683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer.
    Li J; Xie H; Ying Y; Chen H; Yan H; He L; Xu M; Xu X; Liang Z; Liu B; Wang X; Zheng X; Xie L
    Mol Cancer; 2020 Oct; 19(1):152. PubMed ID: 33121495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. METTL3-Induced miR-222-3p Upregulation Inhibits STK4 and Promotes the Malignant Behaviors of Thyroid Carcinoma Cells.
    Lin S; Zhu Y; Ji C; Yu W; Zhang C; Tan L; Long M; Luo D; Peng X
    J Clin Endocrinol Metab; 2022 Jan; 107(2):474-490. PubMed ID: 34562008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. METTL3 promotes colorectal cancer metastasis by promoting the maturation of pri-microRNA-196b.
    Huang L; Liang D; Zhang Y; Chen X; Chen J; Wen C; Liu H; Yang X; Yang X; Lin S
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):5095-5108. PubMed ID: 36348020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of the KDM5A/miRNA-495/YTHDF2/m6A-MOB3B axis facilitates prostate cancer progression.
    Du C; Lv C; Feng Y; Yu S
    J Exp Clin Cancer Res; 2020 Oct; 39(1):223. PubMed ID: 33087165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The m6A methyltransferase METTL3 promotes osteosarcoma progression by regulating the m6A level of LEF1.
    Miao W; Chen J; Jia L; Ma J; Song D
    Biochem Biophys Res Commun; 2019 Aug; 516(3):719-725. PubMed ID: 31253399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-338-5p inhibits cell growth and migration via inhibition of the METTL3/m6A/c-Myc pathway in lung cancer.
    Wu H; Li F; Zhu R
    Acta Biochim Biophys Sin (Shanghai); 2021 Mar; 53(3):304-316. PubMed ID: 33355622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. METTL3 promotes choriocarcinoma progression by activating the miR-935/GJA1 pathway in an m6A-dependent manner.
    Wang W; Shi J; Zheng L
    Am J Reprod Immunol; 2023 Nov; 90(5):e13791. PubMed ID: 37881126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.